Introduction

36
The cyclic nucleotide phosphodiesterases (PDEs) comprise a superfamily of phosphohydrolases that smooth muscle lowering urethral pressure and thus affecting the dynamic component of the disease (17-62 19) . However, the prostate size may also be affected since an anti-proliferative effect of PDE5 inhibitors 63 on prostate stromal cells has been reported (20, 21) . Elevated cGMP levels have been reported in prostate 64 tissue after treatment with PDE5 inhibitors (17) . It is thought that similar to the corpus cavernosum, the Total cell extracts were prepared and analyzed by western blotting as described previously (22) . Primary 154 antibodies were used at dilutions of 1:1000 (PDE5, p-ERK1/2, p-SMAD, SMAD2/3, IGFBP3) or 1:5000 155 (SMA, α-tubulin, β-actin) 156 157
Statistics 158
Results are expressed as mean values ± SEM. Statistical differences between treatments were calculated 159 by paired Student's t-test and regarded significant when P < 0.05 (* P < 0.05, ** P < 0.01).
PDE5 is predominantly expressed in the stromal compartment of the prostate 163
To identify the potential target cells of PDE5 inhibitors in the prostate the expression of PDE5 in 164 humanprostateprimaryprostaticbasalepithelial(PrEC)andstromalcells(PrSC)wasanalyzedby 165 qPCR. Expression of PDE5 was significantly 65±19 fold higher in PrSCs compared with PrECs, a 166 findingconfirmedattheproteinlevelincelllysates (Fig.1A) .Giventhereportedanti-proliferative 167 effects of PDE5 inhibitors we evaluated the impact on primary prostate cell proliferation. Of the 168 three PDE5 inhibitors approved for the treatment of ED Tadalafil was used herein due to its higher 169 specificity for PDE5 over other PDE isoenzymes and its prolonged half-life in plasma (17.5 h vs. ~4 h for and PDE11A were expressed at similar levels) PDE11A expression was very low in both, PrECs
To verify whether the PDE5 expression pattern observed in vitro reflects that in vivo, prostate tissue compartment strong staining was observed while in the epithelial compartment no PDE5 specific immunoreactivity was detectable (Fig. 1C ). Signals could be specifically blocked by PDE5 blocking 180 peptide. Collectively, these results demonstrate that in the human prostate PDE5 is predominantly 181 expressed in the fibromuscular stromal compartment.
183
Tadalafil reduces PrSC proliferation in a dose-dependent manner 184
The effect of PDE5 inhibition by Tadalafil (2.5 µM and 25 µM) on the proliferation of primary prostate These data further demonstrate that the stroma is the main target of PDE5 inhibition in the prostate. Thus, 
203
Since cGMP has been reported to activate the MEK/ERK pathway independently of PKG (26), PrSCs 204 were also pretreated with the MEK1 inhibitor PD98059. However, preincubation with PD98059 did not 205 influence the effect of Tadalafil on proliferation (86±4% vs. 83±5%; P=0.34; Fig. 2D ), demonstrating that 206 the growth inhibition by Tadalafil is not mediated via MEK/ERK.
208
Tadalafil suppresses TGFβ1-mediated fibroblast-to-myofibroblast transdifferentiation 209
Besides stromal expansion the main histological change in the BPH stroma is transdifferentiation of 210 fibroblasts to myofibroblasts/SMCs. This transdifferentiation can be modeled in vitro by stimulating PrSC also marked by typical changes in cell morphology from the thin and elongated phenotype of fibroblasts to 217 the flattened phenotype of myofibroblasts with actin bundles that stain positive for SMA ( Fig. 3C ).
218
The effect of PDE5 inhibition on PrSC transdifferentiation was studied by stimulation with TGFβ1 after 219 preincubation with 25 µM Tadalafil. TGFβ1-induced transdifferentiation was significantly attenuated by (Fig. 5B ). Therefore we 253 tested implication of the MEK/ERK pathway since as mentioned above cGMP has been reported to molecules. To verify that the attenuation of fibroblast-to-myofibroblast transdifferentiation via Tadalafil 265 was by direct inhibition of PDE5 we analyzed the effect of siRNA-mediated PDE5 knockdown. PDE5 266 siRNA significantly reduced PDE5 mRNA and protein levels compared to cells treated with scrambled 267 siRNA (Fig. 6A) . Additionally, the induction of transdifferentiation markers upon TGFβ1 stimulation was 268 significantly reduced by PDE5 knockdown (SMA: 48±8% of SCR control, P=0.01; IGFBP3: 62±19% of 269 SCR control, P=0.03; Fig. 6B ). Transdifferentiation of PrSC had lower efficiency in PDE5 knockdown 270 cells as monitored by SMA and IGFBP3 protein levels (Fig 6C and D) . Taken together siRNA-mediated 
282
In the present study we demonstrated that specific PDE5 inhibition by Tadalafil reduced cellular 
554
Additionally, elevated cGMP levels attenuate fibroblast-to-myofibroblast transdifferentiation 555 independently of PKG activation and thereby reduces the BPH related increase of the myofibroblast ratio.
556
Since attenuation of transdifferentiation in part is blocked the MEK inhibitor PD98059, these effects are 557 mediated via MEK1 signaling. Taken together both distinct pathways activated by Tadalafil reduce 558 cellular changes in the stroma associated with development and progression of BPH, thus indicating 559 potential therapeutic use of PDE5 inhibiton to prevent and treat the disease. 
